Radiochemotherapy in patients with primary glioblastoma comparing two temozolomide dose regimens: is the survival really so impressive?: in regard to Combs et al. (Int J Radiat Oncol Biol Phys 2008;71:999-1005).
Jalali
Rakesh
R
D018906:Antineoplastic Agents, Alkylating / Q000009:adverse effects / Q000627:therapeutic use*; D001932:Brain Neoplasms / Q000188:drug therapy / Q000401:mortality* / Q000532:radiotherapy; D003131:Combined Modality Therapy / Q000009:adverse effects / Q000706:statistics & numerical data; D003606:Dacarbazine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005500:Follow-Up Studies; D005909:Glioblastoma / Q000188:drug therapy / Q000401:mortality* / Q000532:radiotherapy; D006801:Humans; D015203:Reproducibility of Results; D016019:Survival Analysis; D015996:Survival Rate; D000077204:Temozolomide; D013997:Time Factors
D018906:Antineoplastic Agents, Alkylating; D003606:Dacarbazine; D000077204:Temozolomide